Zidovudine

also known as AZT · ZDV · Retrovir · Azidothymidine · 3'-Azido-3'-Deoxythymidine · Retrovir(R) · ZCV · ZDV: zidovudine, azidothymidine, Retrovir

Small molecule

Developed for: HIV infectious disease · AIDS · Kaposi's sarcoma · lipodystrophy · lymphoma · AIDS dementia complex · tuberculosis · non-Hodgkin lymphoma
+19 more
· adult T-cell leukemia/lymphoma · Aicardi-Goutieres syndrome · AIDS related complex · brain disorder · cytomegalovirus retinitis · Epstein-Barr virus-associated lymphoproliferative disorder · hepatitis B virus infection · KSHV inflammatory cytokine syndrome · lymphoproliferative syndrome · multicentric Castleman disease · neuromuscular disease · peripheral T-cell lymphoma, not otherwise specified · post-transplant lymphoproliferative disease · primary biliary cholangitis · progressive multifocal leukoencephalopathy · psoriasis · tropical spastic paraparesis · central nervous system disorder · dementia
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Glaxo Wellcome · Bristol-Myers Squibb · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hoffmann-La Roche · Gilead Sciences
+115 more
· Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · Abbott · Boehringer Ingelheim · GlaxoSmithKline · Harvard School of Public Health (HSPH) · Pharmacia and Upjohn · University of Miami · ANRS, Emerging Infectious Diseases · French National Agency for Research on AIDS and Viral Hepatitis · G D Searle · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Kirby Institute · Makerere University · Research Institute for Development · Upjohn · ViiV Healthcare · AIDS Malignancy Consortium · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Amgen · Genentech, Inc. · International Antiviral Therapy Evaluation Center · National Center for AIDS/STD Control and Prevention, China CDC · National Heart, Lung, and Blood Institute (NHLBI) · Sandoz · St Vincent's Hospital, Sydney · University of California, San Diego · AIDS Project Los Angeles · Amsterdam UMC, location VUmc · Assistance Publique - Hôpitaux de Paris · Axcan Pharma · Beijing YouAn Hospital · Biogen · Botswana Harvard Health Partnership · Botswana Ministry of Health · Brigham and Women's Hospital · CIHR Canadian HIV Trials Network · Centers for Disease Control and Prevention · Centre Hospitalier Universitaire Saint Pierre · Centre de Sante de Ziguinchor, Casamance, Senegal · Centro di Riferimento Oncologico - Aviano · China Medical University, China · Chiron Corporation · Chulalongkorn University · Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal · Department for International Development, United Kingdom · Doris Duke Charitable Foundation · Duke University · Dupont Merck · Fight AIDS and Infectious Diseases Foundation · First Affiliated Hospital of Guangxi Medical University · Fundacion SEIMC-GESIDA · Garvan Institute of Medical Research · Genelabs Technologies · Germans Trias i Pujol Hospital · Guangdong Provincial Maternal and Child Health Hospital · HIV Prevention Trials Network · Hoechst Marion Roussel · Infectious Diseases Institute, Uganda · Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · Janssen Pharmaceutica · Janssen Research & Development, LLC · Janssen-Cilag GmbH · Johann Wolfgang Goethe University Hospital · Kibongoto National Tuberculosis Hospital, Tanzania · Kilimanjaro Christian Medical Centre, Tanzania · Los Angeles County Department of Public Health · Los Angeles LGBT Center · Maternal and Child Health Hospital of Guangxi Province · Maternal and Child Health Hospital of Sichuan Province · Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region · Maternal and Child Health Hospital of Yunan Province · Mbarara University of Science and Technology · all 121 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (7)	US (FDA)	RETROVIR	—	1990-01-12 – 2009-11-06	fda.gov ↗
Approved	EU (EMA)	Combivir	—	1998-03-18	europa.eu ↗
Approved	US (FDA)	RETROVIR	—	1987-03-19	fda.gov ↗

Trials 274 · started per year

today

US approved 1987

EU approved 1998

19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02655471	Jul 2017 → Mar 2019	tropical spastic paraparesis	Universidad Peruana Cayetano Heredia	Completed	No outcome recorded
Phase 151 trials · 1 missed
Phase 1	NCT00470041	Jun 2007 → Oct 2009	—	University Ghent	Completed	No outcome recorded
Phase 1	NCT02249416	Nov 2001 → Feb 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00001644	Mar 1997 → Feb 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000696	? → Nov 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000661	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000986	? → Jan 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000755	? → Mar 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000701	? → Feb 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001002	? → Jun 1991	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001010	? → Oct 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000976	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002096	—	HIV infectious disease, cytomegalovirus infection	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00000978	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001113	? → Mar 1990	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001106	? → Mar 1994	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000818	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000728	? → Apr 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000888	? → Apr 2001	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000628	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00002183	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00000705	? → Mar 1989	HIV infectious disease, hemophilia A	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000987	? → Apr 1992	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000656	? → Nov 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00004736	—	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00014014	? → Aug 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000742	? → Oct 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000862	? → Nov 2003	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002006	—	HIV infectious disease	Sandoz	Completed	No outcome recorded
Phase 1	NCT00000753	? → Feb 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000902	? → Apr 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000652	? → Nov 1995	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00000743	? → May 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000695	? → Jul 1991	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000878	? → Oct 2001	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002326	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 1	NCT00000629	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000865	? → Apr 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002014	—	HIV infectious disease	Glaxo Wellcome	Completed	Missed primary
Phase 1	NCT00000725	? → Feb 1990	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000694	? → Aug 1992	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001049	? → Jun 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000944	? → Mar 2003	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000800	? → Oct 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000810	? → Jan 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000967	? → Sep 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002255	—	HIV infectious disease	Amgen	Completed	No outcome recorded
Phase 1	NCT00000920	? → Apr 2003	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000999	? → Mar 1989	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001007	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000685	? → Feb 1990	HIV infectious disease, kidney disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 1	NCT00000814	? → Nov 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT00672412	Oct 2008 → Jan 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00432016	Feb → May 2007	HIV infectious disease	RFS Pharma, LLC	Completed	No outcome recorded
Phase 270 trials · 2 met primary · 2 missed
Phase 2	NCT03922724	Apr 2019 → Jun 2027 expected	lymphoproliferative syndrome, peripheral T-cell lymphoma, not otherwise specified	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT03602690	Oct 2018 → Apr 2022	HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 2	NCT02737046	Dec 2016 → Dec 2024	adult T-cell leukemia/lymphoma	University of Miami	Completed	No outcome recorded
Phase 2	NCT02363452	Sep 2015 → Jan 2018	Aicardi-Goutieres syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01441063	Sep 2011 → Jun 2018	multicentric Castleman disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01419561	Sep 2011 → Dec 2028 expected	KSHV inflammatory cytokine syndrome, human herpesvirus 8 infection	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT00949234	Mar → Jun 2010	HIV infectious disease	University of California, Los Angeles	Completed	No outcome recorded
Phase 2	NCT01964755	Apr 2009 → Jun 2018	Epstein-Barr virus-associated lymphoproliferative disorder, post-transplant lymphoproliferative disease	University of Miami	Terminated	No outcome recorded
Phase 2	NCT00109590	Jun 2006 → Oct 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00270296	Jun 2006 → Mar 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00099632	Mar 2006 → Apr 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00307151	Dec 2005 → Dec 2010	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	Met primary
Phase 2	NCT00217503	Jul 2005 → Jun 2007	lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00142337	Dec 2004 → May 2006	HIV infectious disease	Research Institute for Development	Completed	No outcome recorded
Phase 2	NCT00146380	Jul 2003 → Jan 2009	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 2	NCT00041327	Oct 2002 → Dec 2006	lymphoma	AIDS Malignancy Consortium	Completed	No outcome recorded
Phase 2	NCT00043953	Aug 2002 → ?	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 2	NCT00006264	Jul 2000 → Mar 2003	lymphoma	AIDS Malignancy Consortium	Completed	No outcome recorded
Phase 2	NCT00003261	May 1997 → ?	lymphoma	Centro di Riferimento Oncologico - Aviano	Unknown	No outcome recorded
Phase 2	NCT00001993	—	HIV infectious disease	G D Searle	Completed	No outcome recorded
Phase 2	NCT00001025	? → May 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002184	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00002086	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00000625	? → Nov 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000891	? → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002079	—	HIV infectious disease	G D Searle	Completed	No outcome recorded
Phase 2	NCT00001066	? → Jan 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001084	? → Dec 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000679	? → Feb 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001067	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000831	? → May 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000918	? → Feb 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000687	? → Jul 1993	HIV infectious disease, Kaposi's sarcoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000671	? → Mar 1992	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001057	? → May 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000990	? → Sep 1992	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000659	? → Jul 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00000791	? → Jul 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001032	? → Apr 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000882	? → May 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001045	? → Oct 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000716	? → Jan 1991	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002190	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00000657	? → Sep 1992	AIDS dementia complex, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000982	? → Sep 1996	HIV infectious disease, brain disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000789	? → Jul 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002357	—	HIV infectious disease	Hoechst Marion Roussel	Completed	No outcome recorded
Phase 2	NCT00002379	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00002347	—	HIV infectious disease	Parexel	Completed	No outcome recorded
Phase 2	NCT00000979	? → Oct 1992	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000838	? → Mar 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002324	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00001063	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000916	? → Aug 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00102206	? → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001095	? → Oct 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001040	? → May 1994	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00001989	—	HIV infectious disease	Genelabs Technologies	Completed	No outcome recorded
Phase 2	NCT00000823	? → Feb 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000983	? → Dec 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000678	? → Jul 1992	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001083	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 2	NCT00000961	? → May 1991	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00000781	? → Sep 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000885	? → Jun 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00021463	? → Feb 2002	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000712	? → Nov 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001085	? → Sep 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001029	? → May 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/35 trials · 2 missed
Phase 2/3	NCT02150993	Jan 2016 → May 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2/3	NCT02369406	May 2015 → Nov 2020 overdue	AIDS	Harvard School of Public Health (HSPH)	Active not recruiting	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00490620	Jan 2004 → Apr 2007	primary biliary cholangitis	University of Alberta	Completed	No outcome recorded
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 341 trials · 6 met primary · 4 missed
Phase 3	NCT03988452	Jul 2019 → Sep 2020	HIV infectious disease	Makerere University	Unknown	Met primary
Phase 3	NCT02231281	Aug 2014 → Aug 2018	—	Yongtao Sun, MD, PhD	Unknown	No outcome recorded
Phase 3	NCT01352715	Mar 2012 → Oct 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Met primary
Phase 3	NCT01511237	Dec 2011 → Jun 2015	HIV infectious disease	Research Institute for Development	Completed	No outcome recorded
Phase 3	NCT01516970	Nov 2011 → Aug 2013	HIV infectious disease	Janssen-Cilag GmbH	Completed	Missed primary
Phase 3	NCT01440569	Sep 2011 → Aug 2012	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00573001	Jul 2008 → Jul 2011	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 3	NCT00102960	Jul 2005 → Sep 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00323544	Oct 2004 → Jun 2007	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00078247	Oct 2004 → ?	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00099359	Feb 2004 → Feb 2011	HIV infectious disease	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00144183	Jan 2003 → Jan 2007	AIDS	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00197613	Dec 2002 → Dec 2007	AIDS	Harvard School of Public Health (HSPH)	Completed	No outcome recorded
Phase 3	NCT00158405	Dec 2002 → Dec 2006	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	Mixed
Phase 3	NCT00386230	Jun 1997 → Aug 2000	HIV infectious disease, pregnancy disorder	Research Institute for Development	Completed	Missed primary
Phase 3	NCT00002371	Jun 1996 → Dec 1997	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00001267	Oct 1990 → Apr 2000	AIDS, AIDS related complex	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 3	NCT00001104	? → Feb 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00006396	? → Nov 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00002320	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00000700	? → May 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000960	? → Jun 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00028327	? → Jul 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002367	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00000702	? → Aug 1990	AIDS dementia complex, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002117	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00001011	? → Feb 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002208	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00000709	? → Feb 1990	AIDS dementia complex, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000637	? → Sep 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002410	—	HIV infectious disease	Dupont Merck	Completed	No outcome recorded
Phase 3	NCT00000994	? → May 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000736	? → Feb 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000682	? → Sep 1992	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00001022	? → Dec 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000651	? → May 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00000750	? → Sep 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00050895	? → Mar 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002334	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded

Phase 435 trials · 3 met primary · 2 missed
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT03642704	Feb 2017 → Sep 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 4	NCT02712801	Apr 2016 → Dec 2021	HIV infectious disease	National Center for Women and Children's Health, China CDC	Completed	No outcome recorded
Phase 4	NCT01275625	Jun 2011 → Oct 2012	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT01075152	Nov 2010 → Oct 2012	AIDS, Cryptococcal meningitis	University of Minnesota	Completed	Missed primary
Phase 4	NCT00955968	Jan 2010 → Aug 2016	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 4	NCT00753324	May 2009 → Jan 2012	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	Met primary
Phase 4	NCT01088516	Dec 2008 → Nov 2011	HIV infectious disease	University of Zambia	Completed	No outcome recorded
Phase 4	NCT00865475	Dec 2008 → Mar 2013	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT01772940	Dec 2008 → Oct 2011	HIV infectious disease	Centre Hospitalier Universitaire Saint Pierre	Completed	Missed primary
Phase 4	NCT00854581	Nov 2007 → Jun 2011	lymphoma, precancerous condition	University of Miami	Terminated	No outcome recorded
Phase 4	NCT02028676	Mar 2007 → Mar 2012	HIV infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 4	NCT00335322	Feb 2007 → Mar 2011	HIV infectious disease	Kirby Institute	Completed	Met primary
Phase 4	NCT00389194	Apr 2006 → Oct 2008	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00356616	Sep 2005 → Jun 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Terminated	No outcome recorded
Phase 4	NCT00084136	May 2005 → May 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Mixed
Phase 4	NCT00618176	Jan 2005 → Sep 2006	HIV infectious disease	Peking Union Medical College	Completed	No outcome recorded
Phase 4	NCT00192621	Nov 2004 → Dec 2006	HIV infectious disease, cardiovascular disorder, glucose metabolism disease, hyperlipidemia +1	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00851630	Jun 2004 → Sep 2007	HIV infectious disease, tuberculosis	Duke University	Completed	No outcome recorded
Phase 4	NCT00082394	Apr 2004 → Mar 2006	HIV infectious disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00127959	Mar 2004 → Aug 2006	HIV infectious disease, hepatitis B virus infection	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00122668	Nov 2003 → Jul 2005	HIV infectious disease, lipodystrophy	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 4	NCT00144157	Jun 2003 → Jul 2006	AIDS	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00122226	Jan 2003 → Jul 2008	HIV infectious disease, lipodystrophy	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 4	NCT00143689	Apr 2002 → Feb 2008	HIV infectious disease	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT00038506	Mar 2002 → Aug 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00011895	Feb 2001 → ?	HIV infectious disease	GlaxoSmithKline	Unknown	No outcome recorded
Phase 4	NCT00005764	May 2000 → ?	HIV infectious disease, lipodystrophy	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00004585	Oct 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00005106	Sep 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00002179	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00002386	—	HIV infectious disease, hemophilia A	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00199121	—	HIV infectious disease	Johann Wolfgang Goethe University Hospital	Unknown	No outcome recorded
Phase 4	NCT00002376	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase not applicable69 trials · 1 met primary
—	NCT03394196	Jul 2018 → May 2020	—	University of Washington	Terminated	No outcome recorded Stop: Business
—	NCT01344148	Feb 2009 → Jun 2011	AIDS	Shanghai Public Health Clinical Center	Unknown	No outcome recorded
—	NCT00872872	May 2008 → Apr 2019	—	Thai Red Cross AIDS Research Centre	Completed	No outcome recorded
—	NCT00120510	Jul 2007 → Sep 2009	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
—	NCT00100568	Jul 2006 → Jun 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00100594	May 2005 → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00080522	Feb 2005 → Jan 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001119	Oct 1999 → Jun 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002411	Mar 1998 → Sep 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00000897	? → Oct 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000732	? → May 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002081	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
—	NCT00002044	—	AIDS dementia complex, HIV infectious disease, neuromuscular disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00001001	? → May 1990	HIV infectious disease, liver disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002001	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000731	? → May 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000993	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000765	? → Jun 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000719	? → Feb 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000670	? → Jul 1989	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001008	? → Mar 1991	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002270	—	HIV infectious disease, progressive multifocal leukoencephalopathy	University of Miami	Completed	No outcome recorded
—	NCT00002312	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00002290	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002046	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002168	—	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00014937	? → Dec 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001997	—	HIV infectious disease	Chiron Corporation	Completed	No outcome recorded
—	NCT00001111	? → Jun 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002203	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002045	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000693	? → Mar 1992	HIV infectious disease, cytomegalovirus retinitis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002307	? → Dec 1994	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002286	—	HIV infectious disease, psoriasis	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000647	? → Dec 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000995	? → Feb 1990	HIV infectious disease, cytomegalovirus infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002048	—	HIV infectious disease, lymphatic system disorder	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002287	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000703	? → Mar 1990	HIV infectious disease, non-Hodgkin lymphoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002007	—	HIV infectious disease	Sandoz	Completed	No outcome recorded
—	NCT00002369	—	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002288	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000723	? → Mar 1990	HIV infectious disease, non-Hodgkin lymphoma	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
—	NCT00002155	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00002284	—	HIV infectious disease, non-Hodgkin lymphoma	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002236	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00000919	? → Nov 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002401	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00002400	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00002276	—	HIV infectious disease, hemophilia A	University of Pittsburgh	Completed	No outcome recorded
—	NCT00002063	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00000734	? → May 1990	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000662	? → May 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000718	? → Sep 1991	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002023	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002035	? → Apr 1992	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002281	—	HIV infectious disease	Amgen	Completed	No outcome recorded
—	NCT00002323	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
—	NCT00006617	? → Jun 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002108	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002020	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00001075	? → Jul 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000965	? → Aug 1993	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000706	? → Dec 1988	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002047	—	HIV infectious disease, chronic renal failure syndrome	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002443	? → Jan 1996	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00001024	? → Jun 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000855	? → Feb 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002285	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Comparator or background therapy133 trials
Phase 0	NCT00719602 Comparator	Aug 2009 → Aug 2013	HIV infectious disease, malaria	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 1	NCT02832778 Background	Nov 2016 → Jan 2018	HIV infectious disease	St Stephens Aids Trust	Unknown	No outcome recorded
Phase 1	NCT02499874 Background	Aug 2015 → Oct 2017	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT00326716 Background	Jun 2006 → Jan 2009	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00032669 Background	Mar 2002 → Apr 2006	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Show all 133 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 10

Date	Issuer	Release
2007-10-29	Gilead Sciences	Results Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗ In the SWEET (Simplification With Easier Emtricitabine and Tenofovir) study, patients who switched from Combivir to Truvada, both in combination with once-daily Sustiva(R) (efavirenz), experienced improvements in a number of treatment-related side effects.
2007-07-23	Gilead Sciences	Results 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of 144-week data from an ongoing clinical trial, Study 934, comparing a once-daily regimen of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Sustiva(R) (efavirenz) to a twice-daily regimen of Combivir(R) (lamivudine/zidovudine) with Sustiva once daily in treatment-naive adults with HIV.
2006-12-15	Gilead Sciences	Results 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934, in the Journal of Acquired Immune Deficiency Syndrome (JAIDS).
2006-08-14	Gilead Sciences	Results 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗ Ninety-six week data are being presented by Joel Gallant, MD, Johns Hopkins University School of Medicine, Baltimore, at the XVI International AIDS Conference taking place August 13-18 in Toronto (Poster # TUPE0064).
2006-01-18	Gilead Sciences	Results Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗ Publication Describes Superior Viral Suppression with Fewer Adverse Events Leading to Discontinuation for Patients Taking Viread and Emtriva at 48 Weeks
2005-02-03	Gilead Sciences	Results Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ Gilead Sciences (Nasdaq:GILD) today announced preliminary 48-week data from the company's Study 934.
2004-10-31	Gilead Sciences	Results Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ Although both triple-drug regimens are relatively convenient, we observed a difference in the two arms, with more patients discontinuing in the Combivir group due to adverse events.
2004-08-26	Gilead Sciences	Results Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ Preliminary results show a statistically significant difference favoring Viread/Emtriva in the percentage of patients who achieved and maintained HIV RNA less than 400 copies/mL at 24 weeks, based on the FDA Time to Loss of Virologic Response algorithm (TLOVR).
2001-06-05	Gilead Sciences	Results Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV gilead.com ↗ The results demonstrate that chain-terminator removal occurs more readily with nucleosides than nucleotides and may contribute to the higher-level of resistance associated with nucleosides.
1998-09-23	Gilead Sciences	Results Gilead Sciences Provides Update on PREVEON® Clinical Program for the Treatment of HIV gilead.com ↗ These data demonstrate that PREVEON has durable anti-HIV activity in treatment-experienced patients, including those infected with strains of HIV resistant to most currently approved therapies.

All press releases naming this drug 10 releases

Date	Issuer	Release
2007-10-29	Gilead Sciences	Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗
2007-07-23	Gilead Sciences	144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗
2006-12-15	Gilead Sciences	96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗
2006-08-14	Gilead Sciences	96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗
2006-01-18	Gilead Sciences	Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗
2005-02-03	Gilead Sciences	Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗
2004-10-31	Gilead Sciences	Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗
2004-08-26	Gilead Sciences	Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗
2001-06-05	Gilead Sciences	Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV gilead.com ↗
1998-09-23	Gilead Sciences	Gilead Sciences Provides Update on PREVEON® Clinical Program for the Treatment of HIV gilead.com ↗

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 417 sources stand behind the page.

Field	Value	Cited text
Known as	Zidovudine	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 408 “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the...” NCT00110305 ↗ “These study will explore how fast NVP is eliminated from women after delivery and to see if given zidovudine/lamivudine (AZT/3TC) for 1 or 2 weeks after NVP discontinuation can...” NCT00872872 ↗ “Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label...” NCT02028676 ↗ “For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing...” NCT01776996 ↗ “Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ Show 398 more sources
Known as	3'-Azido-3'-Deoxythymidine	“Phase I Trial of the Combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and Recombinant Interleukin-2” NCT00001005 ↗
Known as	Azidothymidine	“The purpose of this study is to see if giving azidothymidine (AZT) to HIV-positive patients with hemophilia is safe and if it is effective in lowering HIV levels and boosting...” NCT00000705 ↗ 2 “A Clinical Study Examining the Pharmacokinetics and Bioavailability of Azidothymidine (AZT, Zidovudine) in Patients With Human Immunodeficiency Virus (HIV) Infection and Hepatic Disease” NCT00001001 ↗ “Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs” NCT00002276 ↗
Known as	AZT	“To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine...” NCT00000751 ↗ 171 “To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will...” NCT00000718 ↗ “The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the...” NCT00432016 ↗ “To compare the effectiveness of zalcitabine ( dideoxycytidine; ddC ) therapy to zidovudine ( AZT ) in the treatment of AIDS or advanced AIDS related complex ( ARC ) in patients...” NCT00000678 ↗ “The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT),...” NCT02363452 ↗ “To compare the efficacy of lamivudine (3TC) and zidovudine (AZT) in combination versus the better of didanosine (ddI) monotherapy or ddI/AZT combination, in symptomatic HIV-1...” NCT00001066 ↗ “To determine if the pharmacokinetics of low doses of zidovudine (AZT) (that is, how fast AZT reaches the blood, what concentration of AZT is attained in the blood, and how long...” NCT00000732 ↗ “Preliminary studies using human liver tissue have shown that valproic acid inhibits the metabolic inactivation of zidovudine (AZT), which may prolong the plasma half-life of...” NCT00000629 ↗ “To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected...” NCT00001057 ↗ “To evaluate the anti-HIV effect of single agent versus combination therapy with zidovudine (AZT) and interferon alfa-2a (IFN-A2a), as measured by p24 protein expression, viral...” NCT00000696 ↗ “Primary: To compare the efficacy of zidovudine ( AZT ) given alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine; ddC ) in delaying the...” NCT00001022 ↗ Show 161 more sources
Known as	Retrovir	“100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) +...” NCT00002369 ↗ 8 “A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic...” NCT00002290 ↗ “To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or...” NCT00002287 ↗ “A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases” NCT00002044 ↗ “To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients.” NCT00002286 ↗ “chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease.” NCT00002045 ↗ “300 mg zidovudine (Retrovir tablets, GlaxoSmithKline)” NCT00966160 ↗ “Retrovir Brand Zidovudine (AZT) Therapy” NCT00000662 ↗ “Retrovir (Zidovudine)” NCT00002168 ↗
Known as	Retrovir(R)	“Zidovudine, or Retrovir(R), is used at a high dose.” NCT00092222 ↗
Known as	ZCV	“Zidovudine (ZCV)” NCT00144183 ↗
Known as	ZDV	“Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ 67 “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive...” NCT00000920 ↗ “A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of...” NCT00002391 ↗ “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “Arm I options are enteric-coated didanosine (ddI-EC) plus lamivudine (3TC), ddI-EC plus zidovudine (ZDV), ZDV plus 3TC (or Combivir), stavudine (d4T) plus 3TC, or ddI-EC plus...” NCT00014937 ↗ “Double reverse transcriptase inhibitor (RTI) therapy consisting of any two therapy combinations of: didanosine (ddI), lamivudine (3TC), stavudine (d4T) or zidovudine (ZDV),...” NCT00002376 ↗ “The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV...” NCT00002203 ↗ “The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during...” NCT00000888 ↗ “Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 ↗ May 2014 “The extent and manner by which HIV nucleoside reverse transcriptase inhibitors contribute to insulin resistance is unclear. We evaluated the effect of zidovudine/lamivudine...” PMID 19898246 ↗ Feb 2010 Show 57 more sources
Known as	ZDV: zidovudine, azidothymidine, Retrovir	“ZDV: zidovudine, azidothymidine, Retrovir” NCT02028676 ↗
Action	Inhibit	“previous studies have shown AZT to be an effective inhibitor of HIV reverse transcriptase” NCT00000695 ↗
Modality	Small molecule	“nucleoside analog” NCT00000781 ↗
Route	Oral	“AZT orally every 8 hours on days 1 through 4” NCT00000629 ↗